Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for 89Zr-immunoPET.
René RaavéGerwin SandkerPierre AdumeauChristian Borch JacobsenFloriane ManginMichel MeyerMathieu MoreauClaire BernhardLaurène Da CostaAdrien DuboisVictor GoncalvesMagnus GustafssonMark RijpkemaOtto BoermanJean-Claude ChambronSandra HeskampFranck DenatPublished in: European journal of nuclear medicine and molecular imaging (2019)
89Zr-labelled DFOcyclo* and DFOcyclo*-trastuzumab showed higher in vitro and in vivo stability than the current commonly used 89Zr-DFO-trastuzumab. DFOcyclo* is a promising candidate to become the new clinically used standard chelator for 89Zr immunoPET.